Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
The US Food and Drug Administration has approved Valturna tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system, an important regulator of blood pressure. This is the first approval for Valturna, which is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or angiotensin receptor blocker monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Beta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Article Search
Sponsor


See Latest Articles


